Di(n-butyl)tin(IV) oxide reacts with the amino glucose analogues, 1,3,4,6-tetra-O-acetyl-2- {[(2Z)-3-carboxy-1-oxo-2-propenyl]amino}-2-deoxy-β-D-glucopyranose (1a) and 1,3,4,6-tetra-O-acetyl-2- [(2-carboxybenzoyl)amino]-2-deoxy-β-D-glucopyranose (2a) to give the complexes bis-[1,3,4,6-tetra-O- acetyl-2-{[(2Z)-3-carboxy-1-oxo-2-propenyl]amino}-2-deoxy-β-D-glucopyranose]-di-n-butyltin carboxylate (1) and bis-{1,3,4,6-tetra-O-acetyl-2-[(2-carboxybenzoyl)amino]-2-deoxy-β-D-glucopyranose}-di-n-butyltin carboxylate (2) which have been characterized by IR and ¹H, ¹³C NMR and MS spectra. The results of in vitro tests show that compound 1 exhibits high cytotoxicity against the tumor cell lines of A-549 and BEL-7402, low cytotoxicity against the tumor cell lines of P388 and HL-60, while compound 2 exhibits high cytotoxicity against the tumor cell lines of HL-60, A-549 and BEL-7402, low cytotoxicity against the tumor cell line of P388. Clone gene analysis shows that compounds 1 and 2 both have hematopoietic cell toxicity at the concentration of 3.82×10^－6 and 3.02×10^－6 mol/L, respectively

Key words: structural characterization, antitumor activity, synthesis, hematopoietic cell toxicity, organotin carboxylate